EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Adverse events with risankizumab in the real world: postmarketing pharmacovigilance assessment of the FDA adverse event reporting system

Yamin Shu, Jing Chen, Yiling Ding, Qilin Zhang

Frontiers in Immunology · 15.05.2023 · 14

DOI: 10.3389/fimmu.2023.1169735 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Frontiers in Immunology, online erschienen am 15.05.2023. Verfasst von Yamin Shu und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China. Hauptthemen laut MEDLINE: Pharmacovigilance, Drug-Related Side Effects and Adverse Reactions. Die Arbeit wurde bisher 49-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Risankizumab, a humanized IgG1 monoclonal antibody that selectively inhibits IL-23, is currently approved for the treatment of moderate-to-severe plaque psoriasis and Crohn’s disease. The real-world safety study of risankizumab in a large- sample population is currently lacking. The aim of this study was to evaluate risankizumab-associated adverse events (AEs) and characterize the clinical priority through the data mining of the Food and Drug Administration (FDA) Adverse Event Reporting System (FAERS).

Methods

Disproportionality analyses were performed by calculating the reporting odds ratios (RORs), deemed significant when the lower limit of the 95% confidence interval was greater than 1, to quantify the signals of risankizumab-related AEs from the second quarter (Q2) of 2019 to 2022 Q3. Serious and non-serious cases were compared, and signals were prioritized using a rating scale.

Results

Risankizumab was recorded in 10,235 reports, with 161 AEs associated with significant disproportionality. Of note, 37 PTs in at least 30 cases were classified as unexpected AEs, which were uncovered in the drug label, such as myocardial infarction, cataract, pancreatitis, diabetes mellitus, stress, and nephrolithiasis. 74.68%, 25.32%, and 0% PTs were graded as weak, moderate, and strong clinical priorities, respectively. A total of 48 risankizumab-related AEs such as pneumonia, cerebrovascular accident, cataract, loss of consciousness, cardiac disorder, hepatic cirrhosis, and thrombosis, were more likely to be reported as serious AEs. The median TTO of moderate and weak signals related to risankizumab was 115 (IQR 16.75–305) and 124 (IQR 29–301) days, respectively. All of the disproportionality signals had early failure type features, indicating that risankizumab-associated AEs gradually decreased over time.

Conclusion

Our study found potential new AE signals and provided valuable evidence for clinicians to mitigate the risk of risankizumab-associated AEs based on an extensive analysis of a large-scale postmarketing international safety database.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

PharmacovigilanceDrug-Related Side Effects and Adverse ReactionsUnited StatesHumansAdverse Drug Reaction Reporting SystemsUnited States Food and Drug AdministrationAntibodies, MonoclonalAntibodies, Monoclonal, Humanized

Stichwörter der Autor:innen

FAERSadverse eventdisproportionalitypharmacovigilancerisankizumab

Substanzen

risankizumabAntibodies, MonoclonalAntibodies, Monoclonal, Humanized

Autor:innen und Institutionen

  • Department of Pharmacy, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
  • Graduate School of Pharmaceutical Sciences, University of Tokyo, Tokyo, Japan.
  • Department of Pharmacy, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.

Förderung

  • National Natural Science Foundation of China

Zitieren

APA

Shu, Y., Chen, J., Ding, Y., & Zhang, Q. (2023). Adverse events with risankizumab in the real world: postmarketing pharmacovigilance assessment of the FDA adverse event reporting system. Frontiers in Immunology, 14. https://doi.org/10.3389/fimmu.2023.1169735

Vancouver

Shu Y, Chen J, Ding Y, Zhang Q. Adverse events with risankizumab in the real world: postmarketing pharmacovigilance assessment of the FDA adverse event reporting system. Frontiers in Immunology. 2023;14. doi:10.3389/fimmu.2023.1169735

BibTeX
@article{Shu2023,
  author = {Shu, Yamin and Chen, Jing and Ding, Yiling and Zhang, Qilin},
  title = {Adverse events with risankizumab in the real world: postmarketing pharmacovigilance assessment of the FDA adverse event reporting system},
  journal = {Frontiers in Immunology},
  year = {2023},
  volume = {14},
  doi = {10.3389/fimmu.2023.1169735}
}
Kostenlos starten →